Last reviewed · How we verify
NCT05948839
pBFS Guided rTMS Over DMPFC for Treatment-Resistant Depression
NA trial testing active rTMS treatment in Treatment Resistant Depression in 170 participants. Status unknown.
1 June 2024
Quick facts
| Lead sponsor | Changping Laboratory |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 170 |
| Start date | 11 July 2023 |
| Primary completion | 1 June 2024 |
| Estimated completion | 1 September 2024 |
| Sites | 3 locations across China |
Drugs / interventions tested
- active rTMS treatment
- sham rTMS treatment
Conditions studied
- Treatment Resistant Depression — all drugs for Treatment Resistant Depression →
- Major Depressive Disorder — all drugs for Major Depressive Disorder →
Sponsor
Changping Laboratory
Who can join
Adults 18 to 65, any sex, with Treatment Resistant Depression or Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigators aim to evaluate the safety and efficacy of pBFS-guided rTMS therapy targeting DMPFC for patients with treatment-resistant depression
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05948839
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of active rTMS treatment
Trials testing the same drug.
- NCT06350396 — pBFS-guided rTMS Over DMPFC for Treatment-Resistant Depression · NA · recruiting
- NCT05964062 — pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Obsessive-Compulsive Disorder · NA · unknown
- NCT05964049 — pBFS Guided rTMS Therapy for Treatment-resistant Obsessive-Compulsive Disorder · NA · unknown
- NCT03159351 — The Antidepressant Effects of rTMS After Ischemic Stroke · NA · unknown
Other recruiting trials for Treatment Resistant Depression
Currently open trials in the same condition.
- NCT07183748 — Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression · Phase 2 · recruiting
- NCT06938841 — Maintenance rTMS for Depression (Maitr-De) · NA · recruiting
- NCT06236711 — Transcranial Direct Current Stimulation (tDCS) as an Adjunctive Treatment for Treatment Resistant Depression (TRD) · NA · active not recruiting
- NCT05774665 — Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression · Phase 2 · active not recruiting
- NCT06895863 — COpenhagen Magnetic Personalized Accelerated Brain Circuit Therapy for Treatment Resistant Depression · NA · recruiting
Other Changping Laboratory trials
Trials by the same sponsor.
- NCT06350396 — pBFS-guided rTMS Over DMPFC for Treatment-Resistant Depression · NA · recruiting
- NCT06255535 — pBFS Guided rTMS Over Cognitive Control Network for ASD · NA · recruiting
- NCT06255561 — pBFS Guided rTMS Over Different Targets for Treatment-Resistant Depression · NA · unknown
- NCT06166082 — Stanford Neuromodulation Therapy (SNT) for the Treatment-Resistant Depression · NA · unknown
- NCT06112652 — Neuromodulation of Different Doses to Treat TRD Guided by pBFS Technique · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05948839 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changping Laboratory
- Last refreshed: 12 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05948839.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing